The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis

Abstract

We investigated the distribution of the magnetic resonance imaging (MRI)-measured response to glatiramer acetate (GA) treatment in multiple sclerosis (MS) using data from a clinical trial of relapsing=remitting (RR) MS. A fixed and a random effects model were used to quantify the between-patient heterogeneity in treatment response, expressed as new enhancing lesion percentage reduction. In 95% of the patients, lesion reduction due to treatment was estimated to range between -20% and -54%, indicating a rather homogeneous effect of GA on MRI-measured disease activity in RRMS.

Keywords

MRI lesions multiple sclerosis shape of GA effect

Get full access to this article

View all access options for this article.

References

Comi G , Filippi M , Wolinsky JS , and the European/Canadian Glatiramer Acetate Study Group . European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis . Ann Neurol 2001; 49: 290-297 .

Sormani MP , Bruzzi P , Miller DH , Gasperini C , Barkhof F , Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials . J Neurol Sci 1999; 163: 74-80 .

Spiegelhalter DJ , Thomas A , Best NG. WinBUGS Version 1.2 User Manual. Cambridge: MRC Biostatistics Unit , 1999.

Paty DW , Li DKB , the UBC MS/MRI Study Group , the IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo controlled trial . Neurology 1993; 43: 662-667 .

Li DK , Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferonbeta1a Subcutaneously in Multiple Sclerosis . Ann Neurol 1999; 46: 197-206 .

Simon JH , Jacobs LD , Campion M , Wende K , Simonian N , Cookfair DL et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis . Ann Neurol 1998; 43: 79-87 .

Rovaris M , Codella M , Moiola L , Ghezzi A , Zaffaroni M et al. Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses . Neurology 2002; 59: 1429-1432 .

Stone LA , Frank JA , Albert PS , Bash CN , Calabresi PA , Maloni H et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure . Neurology 1997; 9: 862-869 .

Sormani MP , Bruzzi P , Comi G , Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients . Neurology 2002; 58: 417-421 .